As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another ...

Guillain-Barré Syndrome (GBS) is a rare neuromuscular ... Current treatments for GBS are limited and often inadequate, with many patients experiencing long-term effects. Researchers are ...

We present a case of Guillain-Barré syndrome in a child who received hepatitis A vaccine 5 days before onset of the clinical symptoms. In our patient, the association of Guillain-Barré syndrome ...

Guillain-Barré syndrome (GBS) is an acute inflammatory ... despite this therapy, some patients still make a slow or incomplete recovery. A recent study (Kuitwaard et al, 2009) aimed to examine ...

In a major relief for patients diagnosed with Guillain-Barré Syndrome (GBS), the Pune Municipal Corporation (PMC) has ...

To beef up its case for tanruprubart, Annexon also announced on Wednesday that a real-world study of the drug likewise showed a “rapid increase in muscle strength” versus current standards of care in ...

The majority of patients simply get a Guillain-Barré Syndrome type condition, which affects motor and sensory function, that is to say, muscle strength and feeling. However, there are some ...

Annexon, Inc. (NASDAQ:ANNX) on Tuesday presented data for its late-stage targeted therapy, tanruprubart (formerly ANX005), ...

Pune: A 16-year-old tabla player from Jalna, who was the first reported Guillain-Barré Syndrome (GBS) case in Pune's ...

Five-year-olds can be goofy. That was my first thought several years ago when my son stumbled and fell to the ground.